<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04451330</url>
  </required_header>
  <id_info>
    <org_study_id>RD.06.SPR.202394</org_study_id>
    <nct_id>NCT04451330</nct_id>
  </id_info>
  <brief_title>A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)</brief_title>
  <acronym>DUAL</acronym>
  <official_title>A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study To Compare Efficacy and Safety of Trifarotene (CD5789) Cream When Used Withan Oral Antibiotic for the Treatment of Severe Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that daily use of topical trifarotene (CD5789) 50
      microgram per gram (mcg/g) cream when used in association with oral antibiotic is safe and
      effective for the treatment of severe AV.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 28, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change in Facial Total Lesion Counts (Inflammatory and Non-inflammatory) from Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Facial Inflammatory Lesions (IL) Counts from Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Facial Non Inflammatory Lesions (NIL) Counts from Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Trifarotene (CD5789) Cream + Doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will apply trifarotene 50 mcg/g cream topically once daily in the evening on the face and will receive one tablet of doxycycline hyclate delayed-release 120 mg orally in the evening on Day 1, 2, 3 for 12 weeks and one tablet in the morning on Day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trifarotene Vehicle + Doxycycline Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will apply vehicle trifarotene 50 mcg/g cream topically once daily in the evening on the face and will receive one tablet of placebo doxycycline hyclate delayed-release 120 mg orally in the evening on Day 1, 2, 3 for 12 weeks and one tablet in the morning on Day 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trifarotene cream</intervention_name>
    <description>Trifarotene 50 mcg/g cream will be applied topically once daily on face for 12 weeks.</description>
    <arm_group_label>Trifarotene (CD5789) Cream + Doxycycline</arm_group_label>
    <other_name>AKLIEF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline hyclate</intervention_name>
    <description>Doxycycline hyclate delayed release 120 mg tablets will be administered orally for 12 weeks.</description>
    <arm_group_label>Trifarotene (CD5789) Cream + Doxycycline</arm_group_label>
    <other_name>DORYX MPC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trifarotene Vehicle</intervention_name>
    <description>Trifarotene 50 mcg/g vehicle cream will be applied topically once daily on face for 12 weeks.</description>
    <arm_group_label>Trifarotene Vehicle + Doxycycline Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline Placebo</intervention_name>
    <description>Doxycycline hyclate delayed release 120 mg placebo tablets will be administered orally for 12 weeks.</description>
    <arm_group_label>Trifarotene Vehicle + Doxycycline Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with clinical diagnosis of acne vulgaris, defined by IGA score of 4
             (Severe)

          -  Participants with at least 20 inflammatory lesions (papules and pustules) and 30 to
             120 non-inflammatory lesions (open comedones and closed comedones) and no more than 2
             nodules (less than [&lt;]1 centimeter [cm] in diameter) on the face, excluding the nose

          -  Agrees to provide written informed consent

          -  Participant is a female of non-childbearing potential (premenarchal or postmenopausal
             [absence of menstrual bleeding for 1 year prior to Screening, without any other
             medical reason], hysterectomy or bilateral oophorectomy)

        Exclusion Criteria:

          -  Participant with any acne cyst on the face

          -  Participants with nodulocystic or conglobate acne, acne fulminans, or secondary acne
             (chloracne, drug-induced acne, etc.)

          -  Participants with facial dermal conditions (example [e.g.] tattoo, skin abrasion,
             eczema, sunburned skin, scars, nevi, etc.) that may interfere with study assessments
             in the opinion of the investigator

          -  Participants who is at risk in terms of precautions, warnings, and contraindications
             for trifarotene or doxycycline hyclate

          -  Currently receiving any prescription testosterone therapy (e.g., testosterone
             cypionate, testosterone enanthate, testosterone pellet, testosterone undecanoate) or
             on a testosterone booster or prescription testosterone (e.g., dehydroepiandrosterone
             [DHEA], Omnadren, Sustanon, testosterone cypionate, testosterone enanthate,
             testosterone propionate, testosterone phenylpropionate) or testosterone supplements
             (e.g., Tribulus).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Galderma Research &amp; Development</last_name>
    <phone>817-961-5000</phone>
    <email>clinical.studies@galderma.com</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 25, 2020</study_first_submitted>
  <study_first_submitted_qc>June 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Trifarotene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

